Holen Sie sich die Stockscreener-App
1.02
0.00%
0.00
Handel nachbörslich:
1.03
0.01
+0.98%
Adial Pharmaceuticals Inc Aktie (ADIL) Neueste Nachrichten
Adial Pharmaceuticals (NASDAQ:ADIL) Coverage Initiated at Rodman & Renshaw - Defense World
RODMAN&RENSHAW Upgrades Adial Pharmaceuticals (NASDAQ:ADIL) to “Strong-Buy” - Defense World
Rodman & Renshaw sets stock target, buy rating on Adial Pharma, cites potential - Investing.com India
ARMISTICE CAPITAL, LLC Acquires New Stake in Adial Pharmaceutica - GuruFocus.com
U.S. STOCKS Oklo, Adial Pharma, Sonos - XM
EXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder - AOL
Adial Pharmaceuticals completes key study for FDA meeting - Investing.com
Adial Pharmaceuticals Announces Positive Topline Results - GlobeNewswire
Adial Pharma's AD04 Drug Hits Key Milestones in Alcohol Use Disorder Treatment Study | ADIL Stock News - StockTitan
This Turning Point Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update - Defense World
Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Adial Pharma Reports Mixed Q3: AUD Drug Study Advances Despite Widening Losses | ADIL Stock News - StockTitan
Adial Pharmaceuticals Appoints Vinay Shah as CFO - Defense World
Adial Pharmaceuticals names new CFO amid strategic growth By Investing.com - Investing.com Australia
Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer - GlobeNewswire
Adial Pharmaceuticals names new CFO amid strategic growth - Investing.com
Adial Pharma Taps Veteran CFO with $150M+ Fundraising Track Record | Key Executive Move | ADIL Stock News - StockTitan
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference - The Manila Times
EXCLUSIVE: Adial Pharmaceuticals Secures Additional US Patent Expanding Intellectual Property Protection Around Its Alcohol Use Disorder Candidate - AOL
Adial Pharmaceuticals patent expands for alcohol disorder drug - Investing.com
Adial Pharmaceuticals patent expands for alcohol disorder drug By Investing.com - Investing.com Canada
Adial Pharmaceuticals Receives Notice of Allowance for U.S. - GlobeNewswire
Adial Pharmaceuticals Commends the National Institute on Alcohol Abuse and Alcoholism's New Definition of Recovery - GlobeNewswire
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Down 46.2% in September - Defense World
Analyzing ADI’s price-to-book ratio for the last quarter - US Post News
Adial Pharmaceuticals completes key study stage for AUD drug - Investing.com
Adial Pharmaceuticals Announces Database Lock in - GlobeNewswire
Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder - StockTitan
Analog Devices Inc. (ADI) Stock: A Year of Declines and Increases - The InvestChronicle
MQS Management LLC Increases Stock Position in Analog Devices, Inc. (NASDAQ:ADI) - Defense World
Addex Therapeutics Reports Profitable H1 2024 - TipRanks
Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit - GlobeNewswire
Recent Insider Activity Could Benefit Adaptimmune Therapeutics Plc ADR (ADAP) - Knox Daily
ADMA Biologics stock soars to all-time high of $19.36 - Investing.com
ADMA Biologics Stock Soars 76.2% in 3 Months: Right Time to Invest? - Yahoo Finance
Adial Pharmaceuticals (NASDAQ:ADIL) versus Galapagos (NASDAQ:GLPG) Head-To-Head Comparison - Defense World
Analog Devices (NASDAQ:ADI) shareholders notch a 17% CAGR over 5 years, yet earnings have been shrinking - Yahoo Finance
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement - Eagle-Tribune
ADM Investor Services Singapore Becomes Abaxx Exchange's Third Clearing and Trading Member - GlobeNewswire
Raymond James lifts Adma Biologics Inc [ADMA] price estimate. Who else is bullish? - The DBT News
Keeping an Eye on Adma Biologics Inc (ADMA) After Insider Trading Activity - Knox Daily
Adma Biologics Inc (NASDAQ:ADMA) stock crossing the finish line today - US Post News
Analytical Overview: Adma Biologics Inc (ADMA)’s Ratios Tell a Financial Story - The Dwinnex
A new trading data show Adaptimmune Therapeutics Plc ADR (ADAP) is showing positive returns. - SETE News
ADIA Nutrition Stakes Claim in $6.7B Industry with Strategic Trademark Expansion - Marketscreener.com
ADMA Biologics set to join S&P SmallCap 600 index By Investing.com - Investing.com Canada
Take off with Applied Dna Sciences Inc (APDN): Get ready for trading - SETE News
ADMA Biologics Set to Join S&P SmallCap 600 Index - Yahoo Finance
Adma Biologics Inc (ADMA) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Adma Biologics Inc (ADMA) Performance and Fundamentals Dashboard tells a completely different story - SETE News
Predicting Adaptimmune Therapeutics Plc ADR’s (ADAP) earnings for the current quarter - US Post News
Balance Sheet Insights: Applied Dna Sciences Inc (APDN)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
The Attractiveness of Investing In Analog Devices Inc. (ADI) is Growing - Knox Daily
Applied Dna Sciences Inc (APDN) is a good investment, but the stock may be undervalued - US Post News
Applied Dna Sciences Inc: Navigating Market Fluctuations with a 14.11M Market Cap - The InvestChronicle
Small-cap stars are buying this forecast-smashing biotech - Citywire New Model Adviser
Q2 2026 EPS Estimates for Analog Devices, Inc. Decreased by Analyst (NASDAQ:ADI) - MarketBeat
Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Declines By 14.5% - Defense World
Analog Devices (NASDAQ:ADI) shareholders notch a 16% CAGR over 5 years, yet earnings have been shrinking - Simply Wall St
0.93%
3.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):